Metacrine to Present at 2021 RBC Global Healthcare Conference
Metacrine, a clinical-stage biopharmaceutical company focused on liver and gastrointestinal disease therapies, will present virtually at the 2021 RBC Global Healthcare Conference on May 18, 2021, at 5:25 p.m. ET. CEO Preston Klassen will lead the presentation, which can be accessed through a live webcast. The company's FXR platform underpins two product candidates: MET409 and MET642, with ongoing clinical trials targeting NASH and type 2 diabetes. Visit Metacrine's website for further details and to access the webcast replay, available for 30 days.
- None.
- None.
SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the 2021 RBC Global Healthcare Conference at 5:25 p.m. ET on Tuesday, May 18, 2021.
A live webcast of the presentation will be available at https://investors.metacrine.com/events-and-presentations. A replay of the webcast will be archived for 30 days following the conference.
About Metacrine
Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies to treat liver and gastrointestinal diseases. Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizing a unique chemical scaffold, which has demonstrated an improved therapeutic profile in clinical trials. The Company’s two product candidates, MET409 and MET642, are currently being investigated in clinical trials as potential new treatments for NASH. MET409 has completed a 12-week monotherapy trial in patients with NASH and is being evaluated in a 12-week combination trial with empagliflozin in patients with both NASH and type 2 diabetes. MET642 has completed a 14-day Phase 1 trial in healthy volunteers and is being evaluated in a 16-week monotherapy trial in patients with NASH. To learn more, visit www.metacrine.com.
Investor & Media Contact
Steve Kunszabo
Metacrine, Inc.
+1 (858) 369-7892
skunszabo@metacrine.com
FAQ
What conference will Metacrine present at on May 18, 2021?
Who will present for Metacrine at the RBC Global Healthcare Conference?
What are the main product candidates being developed by Metacrine?
How can I access the Metacrine presentation at the RBC Global Healthcare Conference?
What is the focus of Metacrine's clinical trials?
